New drug combo shows promise for Tough-to-Treat endometrial cancer
NCT ID NCT05156268
First seen Apr 29, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This phase II trial tested whether combining two drugs, pembrolizumab and olaparib, could help people with persistent or recurrent endometrial cancer or carcinosarcoma. The study enrolled 26 participants and looked at how many responded to treatment and what side effects occurred. The goal was to find a more effective option for those whose cancer has come back or not gone away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Suffolk-Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab and olaparib
What this could lead to
If this combination works, it could offer a new treatment option for people with persistent or recurrent endometrial cancer that has not responded to standard therapies.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply to everyone. The drug combination may cause side effects or may not shrink tumors effectively.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.